hrcak mascot   Srce   HID

Ostalo

Potential Cardio-protective Effects of Psoriasis Medications

Brian Liu ; Rutgers New Jersey Medical School
Robert A. Schwartz ; Dermatology Rutgers New Jersey Medical School

Puni tekst: engleski, PDF (119 KB) str. 249-249 preuzimanja: 144* citiraj
APA 6th Edition
Liu, B. i A. Schwartz, R. (2018). Potential Cardio-protective Effects of Psoriasis Medications. Acta Dermatovenerologica Croatica, 26 (3), 249-249. Preuzeto s https://hrcak.srce.hr/207012
MLA 8th Edition
Liu, Brian i Robert A. Schwartz. "Potential Cardio-protective Effects of Psoriasis Medications." Acta Dermatovenerologica Croatica, vol. 26, br. 3, 2018, str. 249-249. https://hrcak.srce.hr/207012. Citirano 27.10.2021.
Chicago 17th Edition
Liu, Brian i Robert A. Schwartz. "Potential Cardio-protective Effects of Psoriasis Medications." Acta Dermatovenerologica Croatica 26, br. 3 (2018): 249-249. https://hrcak.srce.hr/207012
Harvard
Liu, B., i A. Schwartz, R. (2018). 'Potential Cardio-protective Effects of Psoriasis Medications', Acta Dermatovenerologica Croatica, 26(3), str. 249-249. Preuzeto s: https://hrcak.srce.hr/207012 (Datum pristupa: 27.10.2021.)
Vancouver
Liu B, A. Schwartz R. Potential Cardio-protective Effects of Psoriasis Medications. Acta Dermatovenerol Croat. [Internet]. 2018 [pristupljeno 27.10.2021.];26(3):249-249. Dostupno na: https://hrcak.srce.hr/207012
IEEE
B. Liu i R. A. Schwartz, "Potential Cardio-protective Effects of Psoriasis Medications", Acta Dermatovenerologica Croatica, vol.26, br. 3, str. 249-249, 2018. [Online]. Dostupno na: https://hrcak.srce.hr/207012. [Citirano: 27.10.2021.]

Sažetak

Psoriasis management can be challenging, complicated sometimes by being associated with other systematic inflammatory diseases including metabolic syndrome, myocardial infarction, hypertension, obesity, diabetes mellitus, and hyperlipidemia. Of particularly concern is its cardiovascular linkage. It is noteworthy and reassuring that some therapeutic options for psoriasis may be cardio-protective. We highlight phototherapy, methotrexate, and TNF alpha inhibitors and other biological agents for psoriasis that may lower the risk of cardiovascular events. Ways to reduce cardiovascular risk in patients with psoriasis should be encouraged. We concur with the conclusion that long-term study is necessary to assess the risks and benefits of biologic therapy, but that persons with preexistent cardiovascular disease or at high risk for it might benefit from medication with cardio-preventive value.

Hrčak ID: 207012

URI
https://hrcak.srce.hr/207012

Posjeta: 265 *